Morgan Stanley
YARW

Morgan Stanley’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Morgan Stanley’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26 Hold
1
– – ﹤0.01% 8132
2025
Q4 		$25 Sell
1
-17
-94% -$341 ﹤0.01% 8049
2025
Q3 		$305 Sell
18
-50
-74% -$1.64K ﹤0.01% 7555
2025
Q2 		$5.63K Sell
68
-188
-73% -$12.2K ﹤0.01% 7007
2025
Q1 		$20.2K Buy
256
+170
+198% +$20.9K ﹤0.01% 6568
2024
Q4 		$14.4K Buy
86
+50
+139% +$6.54K ﹤0.01% 6674
2024
Q3 		$3.38K Hold
36
– – ﹤0.01% 7013
2024
Q2 		$3.54K Sell
36
-1
-3% -$125 ﹤0.01% 6944
2024
Q1 		$5.74K Sell
37
-38
-51% -$4.09K ﹤0.01% 6857
2023
Q4 		$8.7K Buy
75
+31
+70% +$4.83K ﹤0.01% 6869
2023
Q3 		$8.8K Hold
44
– – ﹤0.01% 6777
2023
Q2 		$9.06K Buy
44
+17
+63% +$4.52K ﹤0.01% 6844
2023
Q1 		$4.08K Buy
27
+1
+4% +$180 ﹤0.01% 7098
2022
Q4 		$3.5K Hold
26
– – ﹤0.01% 7243
2022
Q3 		$6K Sell
26
-21
-45% -$6.72K ﹤0.01% 7220
2022
Q2 		$16K Sell
47
-3
-6% -$1.26K ﹤0.01% 7077
2022
Q1 		$29K Sell
50
-92
-65% -$54.7K ﹤0.01% 6981
2021
Q4 		$131K Sell
142
-74
-34% -$79.4K ﹤0.01% 6287
2021
Q3 		$271K Sell
216
-10
-4% -$19.4K ﹤0.01% 5839
2021
Q2 		$713K Buy
226
+184
+438% +$728K ﹤0.01% 5291
2021
Q1 		$258K Sell
42
-3
-7% -$21.8K ﹤0.01% 5506
2020
Q4 		$256K Sell
45
-44
-49% -$276K ﹤0.01% 5466
2020
Q3 		$533K Sell
89
-158
-64% -$922K ﹤0.01% 4613
2020
Q2 		$1.54M Sell
247
-19
-7% -$129K ﹤0.01% 3831
2020
Q1 		$2.57M Buy
266
+260
+4,333% +$4.08M ﹤0.01% 3126
2019
Q4 		$106K Buy
6
+4
+200% +$66.7K ﹤0.01% 5635
2019
Q3 		$31K Buy
+2
New +$32.3K ﹤0.01% 5889
2019
Q2 		– Sell
-10
Closed -$247K – 6421
2019
Q1 		$280K Sell
10
-15
-60% -$360K ﹤0.01% 4883
2018
Q4 		$371K Buy
25
+6
+32% +$134K ﹤0.01% 4985
2018
Q3 		$677K Buy
19
+15
+375% +$463K ﹤0.01% 4811
2018
Q2 		$111K Hold
4
– – ﹤0.01% 5715
2018
Q1 		$540K Buy
+4
New +$486K ﹤0.01% 4959

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley's YARW Position: Q1 2026 in Review

Morgan Stanley held its Yarrow Bioscience, Inc. Common Stock (YARW) position steady in Q1 2026 at 1 share worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #8132.

Morgan Stanley first reported a position in YARW in Q1 2018 and has held it in 32 quarters since. The position peaked at $2.57M in Q1 2020. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • Morgan Stanley held 1 share of Yarrow Bioscience, Inc. Common Stock worth $26 as of Q1 2026.
  • Morgan Stanley left its Yarrow Bioscience, Inc. Common Stock share count unchanged in Q1 2026.
  • Yarrow Bioscience, Inc. Common Stock made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8132 holding.
  • Morgan Stanley first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2018 and has held it in 32 quarters since.
  • Morgan Stanley's Yarrow Bioscience, Inc. Common Stock position peaked at $2.57M in Q1 2020.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.